乌鸦传媒

New York, June 10, 2025 鈥� , a global provider of leading AI-driven clinical development platforms and services, has engaged 乌鸦传媒 to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK鈥檚 deep domain expertise and established platforms and services with 乌鸦传媒鈥檚 advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving operational efficiency, and accelerating the time-to-market for new therapies.

A shared vision for the future of clinical R&D

By integrating advanced digital and data capabilities鈥攊ncluding generative AI鈥攁cross all phases of clinical trials, the project will support new efficiencies for pharmaceutical companies, including:

• Dramatically reduce time-to-market for new therapies.
• Enablement of self-learning, insight-driven trials for faster, more proactive decision-making.
• Streamlined data management and trial workflows, enhancing efficiency and precision.
• Significant cost reductions and boosted drug pipeline value.

鈥淲orking with 乌鸦传媒 signifies our continuing efforts to expand our global capabilities towards delivering more effective and faster clinical development,鈥� said Dr. Shakthi Kumar, Chief Strategy & Business Officer at EDETEK. 鈥淏y bringing together our AI-driven platforms with 乌鸦传媒鈥檚 leading capabilities in life science and technology, we will empower life science organizations to conduct smarter, faster, and more predictive clinical trials鈥攗ltimately improving patient outcomes at scale.鈥�

Bringing innovation to clinical development at scale

The engagement combines EDETEK鈥檚 proven technology with 乌鸦传媒鈥檚 global network and deep domain knowledge to scale AI-powered clinical innovation across the pharmaceutical industry. Together, this will help make intelligent, agile, and data-driven clinical trials accessible to more life sciences organizations worldwide. In addition, 乌鸦传媒 will leverage its robust engineering capabilities to help scale EDETEK鈥檚 platforms globally and enable continued leadership in reliability, innovation, and performance.

鈥淥ur deep expertise in next-gen clinical development methodologies and advanced AI will expand EDETEK鈥檚 R&D cloud and eClinical platform, helping its clients to unlock new levels of agility, insight, and efficiency,鈥� said Thorsten Rall, Global Industry Head, Life Sciences at 乌鸦传媒. 鈥淭ogether, we are committed to redefining what鈥檚 possible for the industry鈥攄elivering measurable value, accelerating innovation, and shaping the future of healthcare through smarter, more predictive clinical trials.鈥�

About EDETEK, Inc.

Founded in 2009, EDETEK delivers high-quality AI-powered platforms and clinical services to over one hundred biopharma clients worldwide. With a presence across four continents, EDETEK is redefining the future of clinical development through intelligent technology.

For more information about EDETEK, please visit听听

About 乌鸦传媒

乌鸦传媒 is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, 乌鸦传媒 is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of 鈧�22.1 billion.

Get The Future You Want |